Hemogenyx Pharmaceuticals (LON:HEMO) Shares Up 10.3% – Here’s Why

Hemogenyx Pharmaceuticals Plc (LON:HEMO)’s share price traded up 10.3% on Monday . The company traded as high as GBX 1,040 and last traded at GBX 1,010. 41,022 shares traded hands during trading, an increase of 24% from the average session volume of 33,059 shares. The stock had previously closed at GBX 916.

Hemogenyx Pharmaceuticals Stock Performance

The company’s fifty day simple moving average is GBX 922.49 and its 200 day simple moving average is GBX 884.97. The stock has a market capitalization of £64.89 million, a P/E ratio of -4.37 and a beta of 1.56. The company has a current ratio of 0.43, a quick ratio of 6.72 and a debt-to-equity ratio of -440.54.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.